These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19136678)

  • 21. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil.
    Cardoso LP; Pereira GA; Viegas AA; Schmaltz LE; Stefani MM
    J Med Virol; 2010 Mar; 82(3):351-7. PubMed ID: 20087934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.
    Asahchop EL; Oliveira M; Brenner BG; Martinez-Cajas JL; Toni Td; Ntemgwa M; Moisi D; Dandache S; Stranix B; Tremblay CL; Wainberg MA
    Antiviral Res; 2010 Sep; 87(3):367-72. PubMed ID: 20541566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
    Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
    Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug resistance in non-subtype B HIV-1.
    Kantor R; Katzenstein D
    J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.
    Abecasis AB; Deforche K; Bacheler LT; McKenna P; Carvalho AP; Gomes P; Vandamme AM; Camacho RJ
    Antivir Ther; 2006; 11(5):581-9. PubMed ID: 16964826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
    Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
    J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir.
    Canducci F; Ceresola ER; Saita D; Al-Abed Y; Garotta G; Clementi M; Nicoletti F
    Antiviral Res; 2011 Sep; 91(3):292-5. PubMed ID: 21763726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal.
    Palma AC; Araújo F; Duque V; Borges F; Paixão MT; Camacho R;
    Infect Genet Evol; 2007 Jun; 7(3):391-8. PubMed ID: 17360244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.
    Vergne L; Snoeck J; Aghokeng A; Maes B; Valea D; Delaporte E; Vandamme AM; Peeters M; Van Laethem K
    FEMS Immunol Med Microbiol; 2006 Feb; 46(1):53-62. PubMed ID: 16420597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
    Bracciale L; Colafigli M; Zazzi M; Corsi P; Meraviglia P; Micheli V; Maserati R; Gianotti N; Penco G; Setti M; Di Giambenedetto S; Butini L; Vivarelli A; Trezzi M; De Luca A
    J Antimicrob Chemother; 2009 Sep; 64(3):607-15. PubMed ID: 19608581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.